Protalix BioTherapeutics
PLX
33 hedge funds and large institutions have $8.72M invested in Protalix BioTherapeutics in 2016 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 7 closing their positions.
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
14% more funds holding
Funds holding: 29 → 33 (+4)
0.27% less ownership
Funds ownership: 2.23% → 1.96% (-0.27%)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
30% less capital invested
Capital invested by funds: $12.5M → $8.72M (-$3.75M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$2.14M |
| 2 |
IAM
Ion Asset Management
Herzliya,
Israel
|
+$1.8M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$1.79M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$958K |
| 5 |
AGC
Angelo Gordon & Co
New York
|
+$472K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$7.43M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$3.56M |
| 3 |
Barclays
London,
United Kingdom
|
-$219K |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$29K |
| 5 |
SIM
Spark Investment Management
New York
|
-$16.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VKH
26
Virtu KCG Holdings
New York
| $5K | -$424 | -95 | -8% |
|
|
PCM
27
Prelude Capital Management
New York
| $5K | +$4.69K | +1,050 | New |
|
28
Bank of America
Charlotte,
North Carolina
| $1K | -$357 | -80 | -25% |
|
|
CCM
29
Camber Capital Management
Boston,
Massachusetts
| – | -$7.43M | -1,327,500 | Closed |
|
|
30
Baillie Gifford & Co
Edinburgh,
United Kingdom
| – | -$3.56M | -636,136 | Closed |
|
|
31
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$29K | -5,070 | Closed |
|
|
FANJ
32
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | -$6K | -1,000 | Closed |
|
33
UBS Group
Zurich,
Switzerland
| – | -$3.88K | -868 | -95% |
|
34
Simplex Trading
Chicago,
Illinois
| – | -$3K | -561 | Closed |
|
|
EDRH
35
Edmond de Rothschild Holding
Chambesy,
Switzerland
| – | -$2K | -367 | Closed |
|
36
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$491 | -110 | -68% |
|
PLX Hedge Fund Activity: Q4 2016 in Review
33 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2016, worth a combined $8.72M — down 30% from $12.5M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new PLX positions and 7 closed out — a net gain of 4 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Highbridge Capital Management, opening a new position worth an estimated $2.14M. The largest seller was Camber Capital Management, exiting entirely with an estimated $7.43M sold.
- 33 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2016, up from 29 in Q3 2016.
- Funds reported $8.72M of Protalix BioTherapeutics stock for Q4 2016, down 30% quarter-over-quarter.
- 11 funds opened new Protalix BioTherapeutics positions in Q4 2016 and 7 closed out, a net change of +4 holders.
- The largest Protalix BioTherapeutics buyer in Q4 2016 was Highbridge Capital Management, an estimated $2.14M added.
- The largest Protalix BioTherapeutics seller in Q4 2016 was Camber Capital Management, an estimated $7.43M sold.
Based on aggregated 13F filings for Q4 2016.